SCHEMBL6030985

SCHEMBL6030985

CCCCCCCCNC(=O)Nc1sc(C(=O)NCc2ccccn2)c(C)c1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HSD17B10 Q99714 2/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
ALOX15 P16050 2/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030396 0.88 EPHX1 (0.43) ALDH1A1MAPTPOLBRAB9ALMNA
SCHEMBL6031389 0.88 ALDH1A1 (0.47) ALDH1A1MAPTPOLBTDP1HSD17B10
SCHEMBL6030385 0.86 NAMPT (0.43) ALDH1A1MAPTPOLBTDP1HPGD
SCHEMBL6030575 0.86 ALDH1A1 (0.43) ALDH1A1MAPTPOLBTDP1HSD17B10
SCHEMBL6029710 0.86 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10HPGDRAB9A
SCHEMBL6029669 0.86 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10HPGDRAB9A
SCHEMBL6031178 0.86 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10HPGDRAB9A
SCHEMBL6030054 0.86 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10HPGDRAB9A
SCHEMBL6029757 0.86 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10HPGDRAB9A
SCHEMBL6029645 0.85 ALDH1A1 (0.49) ALDH1A1POLBHSD17B10HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885MAPT 4105/4885POLB 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.